ArticleCancer immunology, immunotherapy : CII2009
Onconeural antibodies in sera from patients with various types of tumours.
Article in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.Neurology(R) neuroimmunology & neuroinflammation · 2023Pooled it
- What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review.BMC psychiatry · 2017Pooled it
- Guideline
- Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.European journal of neurology · 2011Guideline
- Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer.Cancer research communications · 2025Article
- Initial screening for neuronal autoantibodies and their putative impact on survival in patients with small-cell lung cancer.Thoracic cancer · 2024Article
- Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview.Molecular diagnosis & therapy · 2021Review
- Low-dose interleukin-2 as a novel therapeutic option for refractory paraneoplastic neurologic syndrome: a case of chronic relapsing anti-Ma2/Ta paraneoplastic myeloradiculopathy.Encephalitis (Seoul, Korea) · 2021Article
- Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives.Cancers · 2021Review
- Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review.Therapeutic advances in drug safety · 2021Article
- Determination of Paraneoplastic neuropathy in newly diagnosed breast tumor patients.eNeurologicalSci · 2020Article
- Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.Nature reviews. Clinical oncology · 2019Review
- Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.Journal of neurology · 2017Article
- Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.Cancer immunology, immunotherapy : CII · 2017Article
- Diagnostics of paraneoplastic neurological syndromes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Review
- Update on neurological paraneoplastic syndromes.Current opinion in oncology · 2015Review
- Paraneoplastic syndromes associated with lung cancer.World journal of clinical oncology · 2014Review
- Paraneoplastic neurological syndromes.Clinical and experimental immunology · 2014Review
- Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry.Oncoimmunology · 2013Review
- Diagnosis and management of paraneoplastic neurologic disorders.Current treatment options in oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe assessed the frequency and levels of onconeural antibodies in 974 patients with various types of tumours, but without apparent paraneoplastic neurological syndromes (PNS). PATIENTS AND
methodsWe included patients with the following tumours: 200 small-cell lung cancer (SCLC) patients, 253 breast cancer patients, 182 ovarian cancer patients, 266 uterine cancer patients and 73 thymoma patients, as well as 52 patients with PNS and cancer and 300 healthy blood donors. Sera were screened for amphiphysin, CRMP5, Hu, Ma2, Ri and Yo antibodies using a multi-well immunoprecipitation technique.
resultsThe most frequently detected antibodies were Hu followed by CRMP5. Ma2, Yo, amphiphysin and Ri antibodies were less common, but each was found at similar frequencies. Onconeural antibodies were present at similar levels in sera from the PNS control group and from cancer patients. Hu antibodies were rare in cancers other than SCLC. CRMP5 was the only antibody found in patients with thymoma and this antibody was more common among patients with thymoma than in other tumour patients. With one exception, coexisting antibodies were only found in patients with SCLC. The presence of onconeural antibodies in SCLC patients was not associated with prolonged survival.
conclusionOnconeural antibodies are associated with various types of tumours suggesting that all antibodies should be included in the serological screening for possible PNS. The levels of onconeural antibody are not sufficiently sensitive to discriminate between cancer patients with PNS and those without.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.